161 related articles for article (PubMed ID: 37307881)
21. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
22. Rethinking the Current American Joint Committee on Cancer TNM Staging System for Medullary Thyroid Cancer.
Adam MA; Thomas S; Roman SA; Hyslop T; Sosa JA
JAMA Surg; 2017 Sep; 152(9):869-876. PubMed ID: 28636692
[TBL] [Abstract][Full Text] [Related]
23. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
[TBL] [Abstract][Full Text] [Related]
24. Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma.
Wang N; Kjellin H; Sofiadis A; Fotouhi O; Juhlin CC; Bäckdahl M; Zedenius J; Xu D; Lehtiö J; Larsson C
Oncotarget; 2016 Apr; 7(16):21332-46. PubMed ID: 26870890
[TBL] [Abstract][Full Text] [Related]
25. The Prediction of Metastases of Lateral Cervical Lymph Node in Medullary Thyroid Carcinoma.
Zhou TH; Zhao LQ; Zhang Y; Wu F; Lu KN; Mao LL; Jiang KC; Luo DC
Front Endocrinol (Lausanne); 2021; 12():741289. PubMed ID: 34867784
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-21 and long non-coding RNA MALAT1 are overexpressed markers in medullary thyroid carcinoma.
Chu YH; Hardin H; Schneider DF; Chen H; Lloyd RV
Exp Mol Pathol; 2017 Oct; 103(2):229-236. PubMed ID: 29107050
[TBL] [Abstract][Full Text] [Related]
27. The role of molecular genetics in the clinical management of sporadic medullary thyroid carcinoma: A systematic review.
Fussey JM; Vaidya B; Kim D; Clark J; Ellard S; Smith JA
Clin Endocrinol (Oxf); 2019 Dec; 91(6):697-707. PubMed ID: 31301229
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.
Gilliland FD; Hunt WC; Morris DM; Key CR
Cancer; 1997 Feb; 79(3):564-73. PubMed ID: 9028369
[TBL] [Abstract][Full Text] [Related]
29. Inclusion of the Number of Metastatic Lymph Nodes in the Staging System for Medullary Thyroid Cancer: Validating a Modified American Joint Committee on Cancer Tumor-Node-Metastasis Staging System.
Wang Z; Tang C; Wang Y; Yin Z; Rixiati Y
Thyroid; 2022 May; 32(5):536-543. PubMed ID: 35350868
[No Abstract] [Full Text] [Related]
30. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis.
Herac M; Niederle B; Raderer M; Krebs M; Kaserer K; Koperek O
APMIS; 2016 Oct; 124(10):839-45. PubMed ID: 27539746
[TBL] [Abstract][Full Text] [Related]
31. Large sporadic thyroid medullary carcinomas: predictive factors for lymph node involvement.
Aubert S; Berdelou A; Gnemmi V; Behal H; Caiazzo R; D'herbomez M; Pigny P; Wemeau JL; Carnaille B; Renaud F; Bouchindhomme B; Leteurtre E; Perrais M; Pattou F; Do Cao C
Virchows Arch; 2018 Mar; 472(3):461-468. PubMed ID: 29388012
[TBL] [Abstract][Full Text] [Related]
32. Correlation of molecular data with histopathological and clinical features in a series of 66 patients with medullary thyroid carcinoma.
Moura MM; Cabrera RA; Esteves S; Cavaco BM; Soares P; Leite V
J Endocrinol Invest; 2021 Sep; 44(9):1837-1846. PubMed ID: 33575974
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
[TBL] [Abstract][Full Text] [Related]
34. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW; Asa SL; Barletta JA; Ghossein RA; Juhlin CC; Jung CK; LiVolsi VA; Papotti MG; Sobrinho-Simões M; Tallini G; Mete O
Endocr Pathol; 2022 Mar; 33(1):27-63. PubMed ID: 35288841
[TBL] [Abstract][Full Text] [Related]
35. Risk factor analysis of distant metastases in patients with primary medullary thyroid cancer: a population-based study.
Su H; Men Q; Hao J; Zhang F
Eur Arch Otorhinolaryngol; 2024 Mar; 281(3):1525-1530. PubMed ID: 38112760
[TBL] [Abstract][Full Text] [Related]
36. Metastatic lymph node ratio can further stratify risk for mortality in medullary thyroid cancer patients: A population-based analysis.
Qu N; Shi RL; Lu ZW; Liao T; Wen D; Sun GH; Li DS; Ji QH
Oncotarget; 2016 Oct; 7(40):65937-65945. PubMed ID: 27588396
[TBL] [Abstract][Full Text] [Related]
37. Comparison of pediatric and adult medullary thyroid carcinoma based on SEER program.
Zhao Z; Yin XD; Zhang XH; Li ZW; Wang DW
Sci Rep; 2020 Aug; 10(1):13310. PubMed ID: 32764626
[TBL] [Abstract][Full Text] [Related]
38. Ultrasonographic characteristics of medullary thyroid carcinoma according to nodule size: application of the Korean Thyroid Imaging Reporting and Data System and American Thyroid Association guidelines.
Hahn SY; Shin JH; Oh YL; Park KW
Acta Radiol; 2021 Apr; 62(4):474-482. PubMed ID: 32493032
[TBL] [Abstract][Full Text] [Related]
39. Small Cell Carcinoma: a Rare Subtype of Thyroid Cancer with Unanticipated Prognosis.
Shi W; Zhao QY; Liu ZM; Wang ST; Liu CP
Curr Med Sci; 2019 Apr; 39(2):265-269. PubMed ID: 31016520
[TBL] [Abstract][Full Text] [Related]
40. Surveillance, Epidemiology, and End Results Database update for pediatric thyroid carcinomas incidence and survival trends 2000-2016.
Tawde A; Jeyakumar A
Int J Pediatr Otorhinolaryngol; 2022 Feb; 153():111038. PubMed ID: 34998202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
